02/12/2025
The TGA has updated safety warnings for GLP-1 and GIP/GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Mounjaro, Saxenda and Trulicity).
If youβre using these medications and have any concerns, please speak with our pharmacists or your GP.
If you or someone you know needs immediate mental health support, please contact:
π Lifeline: 13 11 14
π Su***de Call Back Service: 1300 659 467
π Beyond Blue: 1300 224 636
π Kids Helpline: 1800 551 800
π 13 YARN: 13 92 76
π QLD Mental Health Access Line: 1300 MH CALL (1300 642 255)
β οΈ Product warnings updated for GLP-1 RA classβ οΈ
*Content advice β this post contains reference to su***de*
We have updated the product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists for two separate safety issues.
This relatively new and high-profile class of medicines is used to treat type 2 diabetes mellitus and/or obesity.
Medicines in the GLP-1 RA class currently marketed in Australia are:
β’ Ozempic (semaglutide)
β’ Wegovy (semaglutide)
β’ Saxenda (liraglutide)
β’ Trulicity (dulaglutide)
β’ Mounjaro (tirzepatide)
1. Potential risk of suicidal thoughts
Product warnings across the GLP-1 RA class of medicines have been aligned to ensure consistent information regarding the potential risk of suicidal thoughts or behaviours.
The updates follow investigations by TGA and other international regulators.
Patients taking any of these medicines should tell their health professional if they experience new or worsening depression, suicidal thoughts or any unusual changes in mood or behaviour.
If you or anyone you know needs help, call Lifeline on 13 11 14.
2. Mounjaro (tirzepatide) and contraception
Our investigation into the potential for reduced effectiveness of oral contraception when first taking or increasing the dose of Mounjaro (tirzepatide) has found that this association could not be ruled out.
As a precautionary measure, the product warnings for tirzepatide have been updated to include further advice for patients using oral contraceptives. Patients taking tirzepatide are advised to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after first taking the medicine and for 4 weeks after each increase in the dose.
None of the GLP-1 RAs should be used during pregnancy and individuals of childbearing potential are advised to use effective contraception during treatment with a GLP-1 RA.
Read more: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/product-warnings-updated-glp-1-ra-class